Influence of Sibutramine on blood pressure: Evidence from placebo-controlled trials

International Journal of Obesity

Volumn 29, Issue 5, 2005, Pages 509-516

  Jordan, J ^a   Scholze, J ^a   Matiba, B ^b   Wirth, A ^c   Hauner, H ^d   Sharma, A M ^e  

^a HUMBOLDT UNIVERSITY   (Germany)

^b ABBOTT GMBH AND CO KG   (Germany)

^c Teutoburger Wald Klinik   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Autonomic; Baroreflex; Catecholamines; Norepinephrine transporter; Sympathetic nervous system

Indexed keywords

PLACEBO; SIBUTRAMINE;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

ADOLESCENT; ADULT; AGED; ANTI-OBESITY AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; CYCLOBUTANES; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; OBESITY; RANDOMIZED CONTROLLED TRIALS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYMPORTERS;

EID: 17844371965     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802887     Document Type: Article

References (30)

1. Popkin BM, Doak CM. The obesity epidemic is a worldwide phenomenon. Nutr Rev 1998; 56: 106-114.
2. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994; 272: 205-211.
3. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-79.
4. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith-West D, Milas NC, Mattfeldt-Beman M, Belden L, Bragg C, Millstone M, Raczynski J, Brewer A, Singh B, Cohen J. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001; 134: 1-11.
5. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB. Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189-198.
6. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van-Gaal LF. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119-2125.
7. Luque CA, Rey JA. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 2002; 440: 119-128.
8. Walsh KM, Leen E, Lean ME. The effect of Sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 1999; 23: 1009-1015.
9. Kahan T, Hjemdahl P, Dahlof C. Relationship between the overflow of endogenous and radiolabelled noradrenaline from canine blood perfused gracilis muscle. Acta Physiol Scand 1984; 122: 571-582.
10. Eisenhofer G, Saigusa T, Esler MD, Cox HS, Angus JA, Dorward PK. Central sympathoinhibition and peripheral neuronal uptake blockade after desipramine in rabbits. Am J Physiol 1991; 260: R824-R832.
11. Esler MD, Wallin G, Dorward PK, Eisenhofer G, Westerman R, Meredith I, Lambert G, Cox HS, Jennings G. Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans. Am J Physiol 1991; 260: R817-R823.
12. Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002; 106: 2459-2465.
13. Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Biaggioni I, Luft FC, Jordan J. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation 2002; 105: 347-353.
14. Tank J, Schroeder C, Diedrich A, Szczech E, Haertter S, Sharma AM, Luft FC, Jordan J. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation 2003; 107: 2949-2954.
15. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G. Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25: 560-563.
16. Scholze J. Adipositasbehandlung mit Sibutramin unter Praxisbedingungen. Deutsche Medizinische Wochenschrift 2002; 127: 606-610.
17. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331-1339.
18. Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K, Study Group. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Exp Clin Endocrinol Diabetes 2004; 112: 201-207.
19. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
20. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991; 10: 1665-1677.
21. Cuellar GE, Ruiz AM, Monsalve MC, Berber A. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res 2000; 8: 71-82.
22. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord 2000; 24: 144-150.
23. Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000; 94: 152-158.
24. Fanghanel G, Cortinas L, Sanchez-Reyes L, Gomez-Santos R, Campos-Franco E, Berber A. Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. Adv Ther 2003; 20: 101-113.
25. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997; 157: 657-667.
26. MacMahon SW, Wilcken DE, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N Engl J Med 1986; 314: 334-339.
27. Reisin E, Abel R, Modan M, Silverberg DS, Eliahou HE, Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 1978; 298: 1-6.
28. Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000; 36: 538-542.
29. Narkiewicz K. Sibutramine and its cardiovascular profile. Int J Obes Relat Metab Disord 2002; 26 (Suppl 4): S38-S41.
30. Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 2002; 16: 13-19.